Oncology
Australia, CAR-T therapy, and solid tumours
Bev Menner, chief executive officer at Cell Therapies Pty Ltd, discusses CAR-T therapies for solid tumours and Australian and APAC R&D more generally.
Market Access
What the revised 340B rebate pilot programme means for pharm...
While the scope of the revised pilot is limited, it may be a harbinger for a broader policy shift.
Digital
Sponsored
AI-enabled pharmacovigilance, with Updesh Dosanjh
Updesh Dosanjh, IQVIA commercialisation lead for safety technology, discusses how and why the role of AI in pharmacovigilance is changing.
Digital
How female leadership can benefit industry
Day One Strategy’s founding partners Abigail Stuart and Hannah Mann share the benefits female leadership can bring to industry.
Patients
Maintenance: The underexamined half of the GLP-1 story
GLP-1 treatments have historically had an exit problem, as appetite suppression stops when the medication stops.
Sales & Marketing
Digital
Market Access
Editor's Picks
Editor's Picks
